公开(公告)号：US20070142351A1

公开(公告)日：2007-06-21

申请号：US11643594

申请日：2006-12-21

Applicant: James Hendrix ,  Joseph Strupczewski ,  Kenneth Bordeau ,  Matthias Urmann ,  Gregory Shutske ,  Horst Hemmerte ,  John Jurcak ,  Harpal Gill ,  Franz Weiberth ,  Thaddeus Nieduzak ,  Sharon Jackson ,  Xu-Yang Zhao ,  Paul Mueller

Inventor： James Hendrix ,  Joseph Strupczewski ,  Kenneth Bordeau ,  Matthias Urmann ,  Gregory Shutske ,  Horst Hemmerte ,  John Jurcak ,  Harpal Gill ,  Franz Weiberth ,  Thaddeus Nieduzak ,  Sharon Jackson ,  Xu-Yang Zhao ,  Paul Mueller

IPC: A61K31/498 ,  A61K31/46 ,  C07D451/02 ,  C07D487/04

CPC classification number: C07D249/08 ,  C07D231/12 ,  C07D233/56 ,  C07D333/58 ,  C07D333/66 ,  C07D333/68 ,  C07D333/70 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D495/04

Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

Abstract translation: 本发明涉及显示与多巴胺D 3受体的选择性结合的杂环取代的酰胺衍生物。 另一方面，本发明涉及在需要这种治疗的患者中治疗与多巴胺D 3 N 3受体活性相关的中枢神经系统障碍的方法，包括向所述受试者施用治疗有效量的所述 用于缓解这种病症的化合物。 可能用这些化合物治疗的中枢神经系统疾病包括心理障碍，物质依赖性，物质滥用，运动障碍（例如帕金森病，帕金森综合征，神经灵敏诱导的迟发性运动障碍，杜氏综合征和亨廷顿疾病），痴呆，焦虑 疾病，睡眠障碍，昼夜节律紊乱和情绪障碍。 本发明还涉及制备本文所述化合物的方法以及制备和使用化合物作为多巴胺D 3受体的显像剂的方法。

公开(公告)号：US07027158B2

公开(公告)日：2006-04-11

申请号：US10229630

申请日：2002-08-28

Applicant: James Hendrix ,  David Wang ,  Michael Ellison ,  Joel Ng

Inventor： James Hendrix ,  David Wang ,  Michael Ellison ,  Joel Ng

IPC: G01N21/45

CPC classification number: G01B11/0625 ,  G01N21/211 ,  G01N21/255 ,  G01N21/55 ,  G01N21/9501

Abstract: A combiner for optical beams includes a substrate overlaid by a multi-layer dielectric film stack. The substrate is a clear material and the dielectric film stack is a series of alternating layer of high and low refractive index. This gives the combiner relatively high reflectivity across UV wavelengths and relatively high transmissivity in the visible and longer wavelengths and allows visible light to pass through the combiner while UV light is reflected. At the same time dielectric film stack has minimal absorption and scatter. This means that the intensity of visible light maintains at least 90% of its intensity as it passes through combiner and UV light retains at least 90% of its intensity as it is reflected by combiner.

公开(公告)号：US20060026945A1

公开(公告)日：2006-02-09

申请号：US10913930

申请日：2004-08-06

Applicant: James Hendrix ,  Donald Hamrick ,  Harold Edwards

Inventor： James Hendrix ,  Donald Hamrick ,  Harold Edwards

IPC: D07B1/06 ,  D02G3/02

CPC classification number: D02G3/047 ,  D01G1/08

Abstract: A process for making a high-strength spun yarn begins by feeding one or more tows of substantially uncrimped continuous filaments of high-modulus material having a tensile modulus exceeding about 20×106 psi through a high-speed stretch-breaking apparatus operating at low total draft ratio (preferably about 2.0) to break the filaments into high-modulus staple fibers having an average length in the range of about 5 to 6 inches. The tows advantageously are heavy, for example, having a denier of about 25,000 to about 500,000. Following the stretch-breaking step, the staple fibers are collected in sliver cans, and the staple fibers are advanced from the sliver cans to a spinning machine, where the fibers are spun into yarn. An important aspect of the invention is that no intermediate processes are performed between the stretch-breaking and spinning processes, which minimizes disruption of the alignment of and damage to the staple fibers.

Abstract translation: 用于制造高强度纺织纱线的方法开始于将具有超过约20×10 -6 psi的拉伸模量的一个或多个基本上未卷曲的高模量材料的连续长丝的丝束通过高速拉伸 - 破裂装置以较低的总通风比（优选约2.0）操作，以将长丝断裂成具有在约5至6英寸范围内的平均长度的高模量短纤维。 丝束有利地是重的，例如，具有约25,000至约500,000的旦尼尔。 在拉伸断裂步骤之后，将短纤维收集在纱条中，并且将短纤维从棉条提前到纺丝机，其中纤维被纺丝成纱线。 本发明的一个重要方面是在拉伸断裂和纺丝过程之间不进行中间工艺，这使得短纤维的对准和损坏的破坏最小化。

公开(公告)号：US07772252B2

公开(公告)日：2010-08-10

申请号：US12425731

申请日：2009-04-17

Applicant: James Hendrix ,  Horst Hemmerle ,  Matthias Urmann ,  Gregory M Shutske ,  Joseph T Strupczewski ,  Kenneth J Bordeau ,  John G Jurcak ,  Thaddeus Nieduzak ,  Sharon A. Jackson ,  Paul Angell ,  James P Carey ,  George Lee ,  David Fink ,  Jean-Francois Sabuco ,  Yulin Chiang ,  Nicola Collar

Inventor： James Hendrix ,  Horst Hemmerle ,  Matthias Urmann ,  Gregory M Shutske ,  Joseph T Strupczewski ,  Kenneth J Bordeau ,  John G Jurcak ,  Thaddeus Nieduzak ,  Sharon A. Jackson ,  Paul Angell ,  James P Carey ,  George Lee ,  David Fink ,  Jean-Francois Sabuco ,  Yulin Chiang ,  Nicola Collar

IPC: A61K31/4535 ,  C07D409/04 ,  C07D409/14 ,  C07D495/04

CPC classification number: A61K31/496 ,  C07D209/08 ,  C07D213/74 ,  C07D215/40 ,  C07D231/12 ,  C07D233/56 ,  C07D239/42 ,  C07D241/04 ,  C07D241/20 ,  C07D249/08 ,  C07D261/20 ,  C07D295/14 ,  C07D295/155 ,  C07D307/66 ,  C07D307/68 ,  C07D317/58 ,  C07D333/58 ,  C07D333/66 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D471/06 ,  C07D495/04 ,  C07D498/04

Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

Abstract translation: 本发明涉及显示与多巴胺D3受体的选择性结合的杂环取代的羰基衍生物。 另一方面，本发明涉及一种治疗需要这种治疗的患者中与多巴胺D3受体活性相关的中枢神经系统障碍的方法，其包括向受试者施用治疗有效量的所述化合物以减轻这种病症。 可能用这些化合物治疗的中枢神经系统疾病包括心理障碍，物质依赖性，物质滥用，运动障碍（例如帕金森病，帕金森综合征，神经灵敏诱导的迟发性运动障碍，杜氏综合征和亨廷顿疾病），痴呆，焦虑 疾病，睡眠障碍，昼夜节律紊乱和情绪障碍。 本发明还涉及本文所述化合物的制备方法以及制备和使用化合物作为多巴胺D3受体的显像剂的方法。

公开(公告)号：US07251036B2

公开(公告)日：2007-07-31

申请号：US11334999

申请日：2006-01-19

Applicant: James Hendrix ,  David Wang ,  Michael Ellison ,  Joel Ng

Inventor： James Hendrix ,  David Wang ,  Michael Ellison ,  Joel Ng

IPC: G01N21/45

CPC classification number: G01B11/0625 ,  G01N21/211 ,  G01N21/255 ,  G01N21/55 ,  G01N21/9501

Abstract: A combiner for optical beams includes a substrate overlaid by a multi-layer dielectric film stack. The substrate is a clear material and the dielectric film stack is a series of alternating layer of high and low refractive index. This gives the combiner relatively high reflectivity across UV wavelengths and relatively high transmissivity in the visible and longer wavelengths and allows visible light to pass through the combiner while UV light is reflected. At the same time dielectric film stack has minimal absorption and scatter. This means that the intensity of visible light maintains at least 90% of its intensity as it passes through combiner and UV light retains at least 90% of its intensity as it is reflected by combiner.

Abstract translation: 用于光束的组合器包括由多层电介质膜叠层覆盖的衬底。 衬底是透明材料，电介质膜堆叠是一系列具有高低折射率的交替层。 这使得组合器在UV波长上相对较高的反射率和可见光和较长波长的相对高的透射率，并且允许可见光在反射UV光的同时通过组合器。 同时电介质薄膜叠层具有最小的吸收和散射。 这意味着当可见光通过组合器时，可见光的强度保持其强度的至少90％，并且当光被组合器反射时，紫外光保持其强度的至少90％。

公开(公告)号：US20060257616A1

公开(公告)日：2006-11-16

申请号：US11127417

申请日：2005-05-12

Applicant: James Hendrix ,  H.W. Gosney

Inventor： James Hendrix ,  H.W. Gosney

IPC: B32B33/00 ,  D04H11/00

CPC classification number: B32B27/36 ,  B32B5/022 ,  B32B5/08 ,  B32B27/12 ,  B32B27/304 ,  B32B27/32 ,  B32B2262/0276 ,  B32B2262/04 ,  B32B2262/062 ,  B32B2262/065 ,  B32B2262/08 ,  B32B2262/12 ,  B32B2262/14 ,  B32B2307/716 ,  B32B2307/7163 ,  B32B2471/02 ,  D06N7/0068 ,  D06N7/0076 ,  D06N2201/02 ,  D06N2201/042 ,  D06N2201/045 ,  D06N2201/06 ,  D06N2201/10 ,  D06N2203/042 ,  D06N2203/048 ,  D06N2209/083 ,  D06N2209/1614 ,  Y10T428/23979 ,  Y10T428/23993

Abstract: A carpet constructed from a biodegradable nonwoven face layer and a backing layer that is biodegradable and/or recyclable. The face layer comprises a needle-punched nonwoven web formed from a blend of different fiber types each of which is biodegradable, the blend comprising face fibers having a relatively high decomposition temperature and thermally activatable binder fibers having a thermal activation temperature lower than the decomposition temperature of the face fibers. The binder fibers bind to one another and to the face fibers. The face fibers can comprise one or more types of fibers that are biodegradable. Suitable fiber types include but are not limited to wool, hemp, cotton, polylactic acid, jute, flax, kanaf, sisal, rayon, and silk. The binder fibers in some embodiments of the invention comprise low-melt polylactic acid.

Abstract translation: 由可生物降解的非织造面层和可生物降解和/或可回收利用的背衬层构成的地毯。 面层包括由不同纤维类型的共混物形成的针刺非织造纤维网，其各自都是可生物降解的，所述共混物包含具有相对较高分解温度的面纤维和具有低于分解温度的热活化温度的热活化粘合纤维 的面纤维。 粘合剂纤维彼此结合并与表面纤维结合。 面纤维可以包括可生物降解的一种或多种类型的纤维。 合适的纤维类型包括但不限于羊毛，大麻，棉花，聚乳酸，黄麻，亚麻，卡那叶，剑麻，人造纤维和丝。 本发明的一些实施方案中的粘合剂纤维包含低熔点聚乳酸。

公开(公告)号：US20050107389A1

公开(公告)日：2005-05-19

申请号：US10960399

申请日：2004-10-07

Applicant: James Hendrix ,  Joseph Strupczeski ,  Kenneth Bordeau ,  Matthias Urmann ,  Gregory Shutske ,  Horst Hemmerle ,  John Jurcak ,  Harpal Gill ,  Franz Weiberth ,  Thaddeus Nieduzak ,  Sharon Jackson ,  Xu-Yang Zhao ,  Paul Mueller

Inventor： James Hendrix ,  Joseph Strupczeski ,  Kenneth Bordeau ,  Matthias Urmann ,  Gregory Shutske ,  Horst Hemmerle ,  John Jurcak ,  Harpal Gill ,  Franz Weiberth ,  Thaddeus Nieduzak ,  Sharon Jackson ,  Xu-Yang Zhao ,  Paul Mueller

IPC: A61K31/33 ,  C07D333/58 ,  C07D333/66 ,  C07D333/68 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D521/00 ,  C07D471/02 ,  A61K31/4745 ,  A61K31/503 ,  C07D487/04

CPC classification number: A61K31/33 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D333/58 ,  C07D333/66 ,  C07D333/68 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D495/04

Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

Abstract translation: 本发明涉及显示与多巴胺D 3受体的选择性结合的杂环取代的酰胺衍生物。 另一方面，本发明涉及在需要这种治疗的患者中治疗与多巴胺D 3 N 3受体活性相关的中枢神经系统障碍的方法，包括向所述受试者施用治疗有效量的所述 用于缓解这种病症的化合物。 可能用这些化合物治疗的中枢神经系统疾病包括心理障碍，物质依赖性，物质滥用，运动障碍（例如帕金森病，帕金森综合征，神经灵敏诱导的迟发性运动障碍，杜氏综合征和亨廷顿疾病），痴呆，焦虑 疾病，睡眠障碍，昼夜节律紊乱和情绪障碍。 本发明还涉及制备本文所述化合物的方法以及制备和使用化合物作为多巴胺D 3受体的显像剂的方法。

公开(公告)号：US20050107377A1

公开(公告)日：2005-05-19

申请号：US10844245

申请日：2004-05-12

Applicant: Gregory Shutske ,  James Hendrix ,  John Jurcak ,  Brian Freed ,  Nicholas Hrib ,  John Tomer ,  Reda Hanna

Inventor： Gregory Shutske ,  James Hendrix ,  John Jurcak ,  Brian Freed ,  Nicholas Hrib ,  John Tomer ,  Reda Hanna

IPC: A61K31/42 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377 ,  C07D498/02

CPC classification number: C07D261/20 ,  C07D333/56 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D498/04

Abstract: The compounds are of the class of benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

Abstract translation: 这些化合物是苯并异恶唑基 - ，吡啶并恶唑基 - 和苯并噻吩基 - 苯氧基衍生物类，其可用作D 4 N 4拮抗剂。 所述化合物可用于治疗通过抑制D 4受体介导的医学病症。 这些病症包括例如注意力缺陷多动障碍，强迫症，精神病，药物滥用，物质依赖性，帕金森病，帕金森综合征，迟发性麻痹症，杜氏综合征，行为障碍和反对性反抗障碍。 本发明的另一方面是提供药物组合物，中间体和制备所述类化合物的方法。

公开(公告)号：US20070161641A1

公开(公告)日：2007-07-12

申请号：US11714047

申请日：2007-03-05

Applicant: James Hendrix ,  Horst Hemmerle ,  Matthias Urmann ,  Gregory Shutske ,  Joseph Strupczewski ,  Kenneth Bordeau ,  John Jurcak ,  Thaddeus Nieduzak ,  Sharon Jackson ,  Paul Angell ,  James Carey ,  George Lee ,  David Fink ,  Jean-Francois Sabuco ,  Yulin Chiang ,  Nicola Collar

Inventor： James Hendrix ,  Horst Hemmerle ,  Matthias Urmann ,  Gregory Shutske ,  Joseph Strupczewski ,  Kenneth Bordeau ,  John Jurcak ,  Thaddeus Nieduzak ,  Sharon Jackson ,  Paul Angell ,  James Carey ,  George Lee ,  David Fink ,  Jean-Francois Sabuco ,  Yulin Chiang ,  Nicola Collar

IPC: A61K31/498 ,  A61K31/497 ,  A61K31/496

CPC classification number: A61K31/496 ,  C07D209/08 ,  C07D213/74 ,  C07D215/40 ,  C07D231/12 ,  C07D233/56 ,  C07D239/42 ,  C07D241/04 ,  C07D241/20 ,  C07D249/08 ,  C07D261/20 ,  C07D295/14 ,  C07D295/155 ,  C07D307/66 ,  C07D307/68 ,  C07D317/58 ,  C07D333/58 ,  C07D333/66 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D471/06 ,  C07D495/04 ,  C07D498/04

Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

Abstract translation: 本发明涉及显示与多巴胺D 3受体的选择性结合的杂环取代的羰基衍生物。 另一方面，本发明涉及在需要这种治疗的患者中治疗与多巴胺D 3 N 3受体活性相关的中枢神经系统障碍的方法，包括向受试者施用治疗有效量的 所述化合物用于缓解这种病症。 可能用这些化合物治疗的中枢神经系统疾病包括心理障碍，物质依赖性，物质滥用，运动障碍（例如帕金森病，帕金森综合征，神经灵敏诱导的迟发性运动障碍，杜氏杜勒氏综合征和亨廷顿病），痴呆，焦虑 疾病，睡眠障碍，昼夜节律紊乱和情绪障碍。 本发明还涉及制备本文所述化合物的方法以及制备和使用化合物作为多巴胺D 3受体的显像剂的方法。

公开(公告)号：US20060225796A1

公开(公告)日：2006-10-12

申请号：US11099894

申请日：2005-04-07

Applicant: James Hendrix

Inventor： James Hendrix

IPC: F16K7/06

CPC classification number: E03D1/00 ,  F16K37/0091 ,  G01F1/34 ,  G01F15/003 ,  G01M3/2815 ,  Y02A20/218 ,  Y10T137/7759 ,  Y10T137/7761 ,  Y10T137/8158 ,  Y10T137/86397

Abstract: A device includes a housing that has a plurality of monolithically formed walls, wherein selected walls are provided with inlet and outlet ports respectively. The housing includes a coupling in fluid communication with the inlet and outlet ports, a mechanism for detecting a fluctuation in water pressure, and a mechanism for selectively prohibiting water flow. The prohibiting mechanism cooperates with the detecting mechanism. The housing also includes a mechanism for providing an audible notification when the water supply is toggled between interrupted and reinstated modes and a mechanism for manually controlling the prohibiting mechanism. The manually controlling mechanism is electrically coupled to the prohibiting mechanism. An internal power supply source supplies power to the detecting mechanism, the prohibiting mechanism, and the manually controlling mechanism. A diode is attached to the housing and is illuminable when the power supply source reaches a minimum threshold level.

Abstract translation: 一种装置包括具有多个整体形成的壁的壳体，其中选定的壁分别设有入口和出口。 壳体包括与入口和出口流体连通的联接器，用于检测水压波动的机构，以及用于选择性地禁止水流的机构。 禁止机制与检测机构配合。 壳体还包括当在中断和恢复模式之间切换供水时提供听觉通知的机构以及用于手动控制禁止机构的机构。 手动控制机构电耦合到禁止机构。 内部电源将检测机构，禁止机构和手动控制机构供电。 二极管连接到壳体，并且当电源达到最小阈值电平时可以点亮二极管。